Amgen Racks Up Positive Phase III Data For Blincyto And Repatha
This article was originally published in The Pink Sheet Daily
Executive Summary
Company announces positive results from a confirmatory study of bispecific antibody Blincyto, on the heels of unveiling positive new data for PCSK9 inhibitor Repatha in statin-intolerant patients.